EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma

by Chan Xiang, PhD, Wei Zhang, PhD, MD, Li-Wen Xiong, MD, Xu-Wei Cai, PhD, MD, Hao-Hua Teng, MD, Rui-Ying Zhao, MD, Zhan-Xian Shang, MD, Han Han-Zhang, PhD, Lu Zhang, PhD, Li Yan, MS, Zhi-Qiu Chen, MS, Yu-Chen Han, PhD, MD
Published 2021-07-01